Last reviewed · How we verify
NCT05763940
Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals
NA trial testing OmegaBoost in Dry Eye Syndromes in 130 participants. Participants enrolled and being followed up; not accepting new ones.
25 May 2024
Quick facts
| Lead sponsor | Western University of Health Sciences |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 130 |
| Start date | 25 May 2022 |
| Primary completion | 25 May 2024 |
| Estimated completion | 25 June 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- OmegaBoost
- Nature Made (soft gel)
- Nature Made (gummy)
Conditions studied
- Dry Eye Syndromes — all drugs for Dry Eye Syndromes →
- Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →
- Omega 3 Index — all drugs for Omega 3 Index →
Sponsor
Western University of Health Sciences
Who can join
18 and older, any sex, with Dry Eye Syndromes or Age-Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine increases in the Omega Index test indicating optimal Omega-3s particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels for overall systemic benefits including healthy cardiovascular health and cholesterol levels as shown in the OmegaIndex (OmegaQuant) research.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05763940
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dry Eye Syndromes
Currently open trials in the same condition.
- NCT07412860 — Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hy · NA · recruiting
- NCT06913504 — Comparison Of Blue Light Filter Feature and Blue Blocking Lenses in Digital Device Users With Dry Eye Patients · NA · active not recruiting
- NCT06913465 — The Impact of Hypothyroidism on Tear Production and Dry Eye Symptoms: Implications for Optometric Care · active not recruiting
- NCT06831253 — Efficacy of Platelet-Rich Plasma Injection in Dry Eye Syndrome · NA · recruiting
- NCT06220474 — Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD · NA · recruiting
Other Western University of Health Sciences trials
Trials by the same sponsor.
- NCT07440030 — The Cervical "STRETCH" Study · NA · not yet recruiting
- NCT06565065 — ImmunoBoost: The Lymphatic Osteopathic Manipulative Treatment Protocol Study · NA · recruiting
- NCT06046183 — Resilience, Grit, and Stress in Medical Students · NA · unknown
- NCT05454007 — Tracking Post-stroke Walking Improvements From the Clinic Into the Home · NA · recruiting
- NCT05926245 — Topical Absorption of Glutathione-cyclodextrin Complex in Healthy Human Subjects Improves Immune Response Against Mycoba · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05763940 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Western University of Health Sciences
- Last refreshed: 24 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05763940.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing